Uwe Grether

The paper identifies foamy microglia as contributors to disease progression in secondary progressive MS, linking oxylipins to lesion expansion and proposing monoacylglycerol lipase as a therapeutic target.

The paper investigates how multiple triggers on an allosteric communication network influence preferential coupling of the CB2R to Gi2 over β-arrestin1, revealing insights into GPCR signaling mechanisms.

This paper develops a TR-FRET-based assay to measure ligand binding kinetics for CB1R and CB2R, finding that D77 enables accurate determination of on- and off-rates for various agonists and antagonists.

CellEKT profiles cellular target engagement of kinase inhibitors using chemical proteomics to determine IC50 values across over 300 kinases and validate results with phosphoproteomics and NanoBRET.

This paper develops and characterizes RNB-61, a potent and selective CB2R agonist with favorable pharmacokinetics, showing nephroprotective effects in kidney injury models.

This study characterizes a novel MAGL inhibitor in a mouse model and human cells, showing its expression in neurovascular unit cells but no effect on blood-brain barrier permeability or cytokine production.